ARGENX SEARGX
時価総額
PER
免疫疾患向けバイオ医薬品の有力企業。FcRn阻害薬やVYVGARTなどの治療薬を展開。2023年7月に12億ドルの公募増資、2023年6月にHYTRULO承認、2030年に第3相5剤・5万人治療目標。米国・欧州・日本中心に展開。
| 2018年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Product net sales | - | - | 401 | 1,191 | 2,186 |
| Collaboration revenue | - | - | 10 | 36 | 4 |
| Other operating income | - | 42 | 35 | 42 | 62 |
| Total operating income | - | 539 | 445 | 1,269 | 2,252 |
| Cost of sales | - | - | 29 | 118 | 227 |
| Research and development expenses | 84 | 581 | 663 | 859 | 983 |
| Selling, general and administrative expenses | - | - | - | - | 1,055 |
| Loss from investment in a joint venture | - | - | -1 | -4 | -8 |
| Total operating expenses | - | 888 | 1,166 | 1,694 | 2,274 |
| Operating loss | -82 | -349 | -720 | -425 | -22 |
| Finance income | - | - | 28 | 107 | 158 |
| Financial expense | - | - | 4 | 1 | 2 |
| Exchange (losses)/gains | - | -50 | -33 | 14 | -48 |
| Profit/(Loss) for the year before taxes | - | -400 | -729 | -304 | 85 |
| Income tax benefit | - | 9 | -20 | -9 | -748 |
| Profit/(Loss) for the year | -67 | -408 | -710 | -295 | 833 |
| Owners of the parent | - | - | -710 | -295 | 833 |
| Basic earnings (loss) per share | - | -7.99 | -13.05 | -5.16 | 13.92 |
| Diluted earnings (loss) per share | - | -7.99 | -13.05 | -5.16 | 12.78 |